C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in shares of BioNTech SE (NASDAQ:BNTX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 9,810 shares of the company's stock, valued at approximately $1,118,000.
Other institutional investors have also recently made changes to their positions in the company. Blue Trust Inc. raised its position in shares of BioNTech by 491.1% in the third quarter. Blue Trust Inc. now owns 467 shares of the company's stock worth $55,000 after buying an additional 388 shares in the last quarter. International Assets Investment Management LLC purchased a new stake in shares of BioNTech in the third quarter worth $21,300,000. Mount Yale Investment Advisors LLC purchased a new stake in shares of BioNTech in the third quarter worth $244,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of BioNTech by 17.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,931 shares of the company's stock worth $465,000 after buying an additional 582 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale raised its position in shares of BioNTech by 12.6% in the third quarter. DekaBank Deutsche Girozentrale now owns 481,397 shares of the company's stock worth $56,886,000 after buying an additional 53,800 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company's stock.
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on BNTX. The Goldman Sachs Group upgraded BioNTech from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $90.00 to $137.00 in a research report on Friday, November 8th. Wells Fargo & Company assumed coverage on shares of BioNTech in a report on Wednesday, December 11th. They set an "overweight" rating and a $170.00 target price for the company. BMO Capital Markets reaffirmed an "outperform" rating on shares of BioNTech in a research report on Monday, December 2nd. Berenberg Bank started coverage on shares of BioNTech in a research report on Tuesday, November 19th. They set a "buy" rating and a $130.00 price objective for the company. Finally, JPMorgan Chase & Co. cut their price objective on shares of BioNTech from $124.00 to $122.00 and set a "neutral" rating for the company in a research report on Tuesday, November 26th. Three analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, BioNTech presently has a consensus rating of "Moderate Buy" and a consensus price target of $142.72.
Read Our Latest Stock Analysis on BioNTech
BioNTech Price Performance
BNTX stock traded up $2.13 during mid-day trading on Friday, hitting $120.01. The company had a trading volume of 1,362,383 shares, compared to its average volume of 746,687. The company has a market capitalization of $28.77 billion, a price-to-earnings ratio of -57.15 and a beta of 0.17. BioNTech SE has a 12-month low of $76.53 and a 12-month high of $131.49. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The company has a 50-day moving average price of $117.27 and a 200 day moving average price of $110.30.
BioNTech Profile
(
Free Report)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
Further Reading
Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
